{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-024232","form_type":"8-K","ticker":"SRTS","cik":"0001494891","company_name":"Sensus Healthcare, Inc.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.907864+00:00","generated_at":"2026-06-25T23:35:42.347313+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sensus Healthcare Q1 revenue $10.3M (+237% YoY); net income $0.97/share; launches new product, share buyback","bullets":["Revenue $10.3M, up 237% YoY; net income $16.1M ($0.97 diluted) vs net loss $1.1M.","Adjusted EBITDA $16.9M vs $(0.8M); gross margin expanded to 69.1% from 51.6%.","Sold non-core asset for $15.0M cash, recorded $12.8M gain; launched TransDermal Infusion product.","Board approved $3.0M share repurchase program; cash balance $32.8M.","Affirms Q2 and FY 2022 profitability expectations."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-024232","json":"https://secwatch.observer/filing/0001213900-22-024232.json","markdown":"https://secwatch.observer/filing/0001213900-22-024232.md","text":"https://secwatch.observer/filing/0001213900-22-024232.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1494891/000121390022024232/0001213900-22-024232-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1494891/000121390022024232/ea159369-8k_sensushealth.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:35:42.347313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}